> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Betta wins EU approval for ALK inhibitor Gevalka across two lines as Q3 turns loss-making
- URL: https://chinapharmadesk.com/betta-ensartinib-eu-approval-label-delta/
- Published: 2026-11-19T14:55:02.000Z
- Updated: 2026-11-19T14:55:06.000Z
- Description: Betta Pharmaceuticals (SZSE: 300558) won European Commission approval (EU/1/26/2078) for Gevalka (ensartinib) in 1L and post-crizotinib ALK+ NSCLC via SFL Pharmaceuticals amid a RMB 44.4m Q3 loss.
- Author: Lin Yi
- Tags: Desk brief, Regulation, Oncology & ADC, Capital

[Betta Pharmaceuticals Co., Ltd.](https://static.cninfo.com.cn/finalpage/2026-11-18/1225677108.PDF?ref=chinapharmadesk.com) (`SZSE: 300558`) disclosed in Shenzhen Stock Exchange announcement No. `2026-074` (dated November 18, 2026) that the European Commission (`EC`) has granted marketing authorization (`EU/1/26/2078`) for its oral anaplastic lymphoma kinase (`ALK`) inhibitor `Gevalka` (`ensartinib dihydrochloride` / `X-396`, 25 mg and 100 mg capsules) for the treatment of adult patients with `ALK`\-positive advanced non-small cell lung cancer (`NSCLC`). While the decision makes `ensartinib` the first Chinese-originated `ALK` inhibitor approved across China (`Bemena`, `Guoyao Zhunzi H20200009/10`), the United States (`Ensacove`, `NDA218171`), and the European Union (`EMEA/H/C/006757`), cross-checking the [European Medicines Agency (EMA) European Public Assessment Report (EPAR) overview](https://www.ema.europa.eu/en/medicines/human/EPAR/gevalka?ref=chinapharmadesk.com) and Betta’s [November 19 share-pledge filing (No. 2026-075)](https://www.bettapharma.com/Investor/viewpdf/src/finalpageK2026-11-19K1225679424.PDF?ref=chinapharmadesk.com) exposes three material operational facts omitted from the headline release: the EU indication covers both first-line and post-crizotinib second-line disease (broader than the U.S. FDA label but narrower than China’s early-stage adjuvant label); the legal EU marketing-authorization applicant on the `EMA` docket is German regulatory consultancy `SFL Pharmaceuticals Deutschland GmbH` rather than Betta’s U.S. subsidiary `Xcovery Holdings, Inc.`; and the approval lands as Betta swung to a Q3 2026 recurring net loss of RMB 44.43 million (approx. $6.15 million) with 61.57% of its controlling shareholder group’s equity pledged against debt.

## Three regulators, three different `ALK+ NSCLC` indication boundaries—and a third-party EU applicant

Following the Committee for Medicinal Products for Human Use (`CHMP`) positive opinion (`EMA/CHMP/205829/2026`) adopted on September 17, 2026, European Commission Decision `EU/1/26/2078` creates a three-way regulatory split across `ensartinib`’s global labels:

| Jurisdiction (Brand & Filing ID)                                       | Legal Applicant / MAH on Regulatory Record                                                                                   | Approved Indication Scope                                                                                                                                                                                                                                                        | Excluded Settings & Commercial Status                                                                                                                                                                                                                                   |
| ---------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **European Union** (Gevalka, EMEA/H/C/006757 / EU/1/26/2078, Nov 2026) | **SFL Pharmaceuticals Deutschland GmbH** (named on EMA EPAR; Betta’s Chinese filing cites subsidiary Xcovery Holdings, Inc.) | **Two lines**: (1) **1L monotherapy** in ALK\-inhibitor-naive advanced NSCLC (eXalt3, NCT02767804); and (2) **2L monotherapy** in advanced NSCLC previously treated with crizotinib                                                                                              | Excludes post-2nd-generation ALK TKI (alectinib/brigatinib) and early-stage adjuvant settings; no European commercial distributor disclosed                                                                                                                             |
| **United States** (Ensacove, NDA218171, Dec 2024)                      | **Xcovery Holdings, Inc.** (Betta majority-owned U.S. subsidiary)                                                            | **One line only**: **1L monotherapy** in adult ALK\+ locally advanced or metastatic NSCLC not previously treated with an ALK inhibitor                                                                                                                                           | Excludes 2L post-crizotinib and early-stage adjuvant settings; NCCN recommended, but U.S. 1L market dominated by lorlatinib (Lorbrena) and alectinib (Alecensa)                                                                                                         |
| **Mainland China** (Bemena, H20200009 / H20200010)                     | **Betta Pharmaceuticals Co., Ltd.**                                                                                          | **Three settings**: (1) **2L post-crizotinib** (Nov 2020); (2) **1L locally advanced/metastatic** (Mar 2022); and (3) **Stage IB–IIIB post-operative adjuvant therapy** (Sept 2026, backed by *NEJM* July 2026 Phase 3 data showing an 80% reduction in disease recurrence risk) | Both 1L and 2L metastatic indications are in the basic NRDL (and included as Item #38 on the [IAC 58-item commercial insurance list](https://chinapharmadesk.com/china-dual-commercial-drug-lists-nhsa-iac/)); adjuvant indication missed the June 30, 2026 NRDL cutoff |

Just as we documented on November 17 in [IMPACT Therapeutics’ (HKEX: 07630) European filing for the PARP inhibitor senaparib (Sepalna, EMEA/H/C/006708)](https://chinapharmadesk.com/impact-senaparib-eu-approval/), because EU pharmaceutical law requires a Marketing Authorisation Holder (`MAH`) to be established inside the European Economic Area (`EEA`), Florida-based `Xcovery Holdings, Inc.` could not hold the centralized EU dossier directly in its own name. The `EMA` EPAR record (`EMA/CHMP/205829/2026`) lists `**SFL Pharmaceuticals Deutschland GmbH**`—the German regulatory-hosting arm of Veristat/SFL—as the formal applicant. Betta’s Announcement No. `2026-074` notes that the company is “actively expanding commercial layouts in emerging markets” but names no European commercial partner or direct sales organization to navigate national Health Technology Assessments (`HTA`) across EU member states, where Roche’s `alectinib` (`Alecensa`) and Pfizer’s `lorlatinib` (`Lorbrena`, which posted a 60% 5-year progression-free survival rate in `CROWN`) already anchor first-line standard of care.

## Why European monetization matters: Q3 2026 recurring losses, a RMB 152.5 million goodwill impairment, and a 61.57% founder share pledge

The absence of disclosed ex-China licensing upfronts or European commercial partnerships for `Gevalka` carries sharper weight when read alongside Betta’s [Q3 2026 financial report (Announcement No. 2026-070, filed October 29, 2026)](https://static.cninfo.com.cn/finalpage/2026-10-29/1225637541.PDF?ref=chinapharmadesk.com) and its [November 19, 2026 share-pledge announcement (No. 2026-075)](https://www.bettapharma.com/Investor/viewpdf/src/finalpageK2026-11-19K1225679424.PDF?ref=chinapharmadesk.com):

| Financial / Governance Metric (SZSE: 300558, PRC GAAP)                    | Q3 2026 (Jul–Sep)                                                          | YoY Change    | 9M 2026 (Jan–Sep)                                                                                      | YoY Change / Sept 30 Balance                                                                      |
| ------------------------------------------------------------------------- | -------------------------------------------------------------------------- | ------------- | ------------------------------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------------------- |
| Operating revenue                                                         | RMB 934.36M (approx. $129.2M)                                              | **\-5.23%**   | RMB 2,910.28M (approx. $402.5M)                                                                        | +7.10%                                                                                            |
| Net income attributable to shareholders                                   | **\-RMB 23.87M (approx. -$3.3M)**                                          | **\-113.49%** | RMB 278.26M (approx. $38.5M)                                                                           | \-12.20%                                                                                          |
| **Recurring net income/loss (Koufei)**                                    | **\-RMB 44.43M (approx. -$6.15M)**                                         | **\-130.31%** | **RMB 158.97M (approx. $22.0M)**                                                                       | **\-52.86%**                                                                                      |
| Asset impairment loss (Shangyu Jianzhi goodwill write-down)               | —                                                                          | —             | **\-RMB 152.46M (approx. -$21.1M)**                                                                    | Goodwill cut 36.86% from RMB 413.58M to RMB 261.12M                                               |
| Cash and bank balances (Huobi Zijin)                                      | —                                                                          | —             | **RMB 705.76M (approx. $97.6M)**                                                                       | +64.14% vs. year-end 2025 (RMB 429.98M)                                                           |
| **Non-current liabilities due within 1 year**                             | —                                                                          | —             | **RMB 1,194.03M (approx. $165.1M)**                                                                    | **+37.11%** vs. year-end 2025 (RMB 870.83M)                                                       |
| Controlling shareholder bloc share pledge (Filing 2026-075, Nov 19, 2026) | **4,485,800 shares newly pledged** to Tibet Trust (1.06% of total capital) | —             | **56,034,800 shares pledged** (69.99% of Kaiming Investment’s stake; **61.57% of concert party bloc**) | **RMB 938.00M (approx. $129.7M)** in loans behind 48.52M pledged shares mature within 6–12 months |

Two balance-sheet pressures stand out from those statutory tables:

1. **Operating margin compression and goodwill write-downs at the corporate level**: While Betta’s 9M 2026 revenue edged up 7.10% to RMB 2.91 billion, cost of goods sold rose 35.19% YoY to RMB 722.36 million and accounts receivable jumped 88.73% from year-end to RMB 662.91 million. Combined with a **RMB 152.46 million goodwill impairment charge** booked in the first nine months of 2026, Q3 recurring net profit swung into a **\-RMB 44.43 million loss**, and cash on hand (`RMB 705.76 million`) covers only 59% of the `RMB 1,194.03 million` in long-term debt maturing within one year.
2. **Rising leverage at the controlling shareholder entity**: On November 19, 2026—one day after disclosing `Gevalka`’s EU approval—Betta announced in Filing No. `2026-075` that its largest shareholder, Ningbo Kaiming Investment Management Partnership (`Ningbo Kaiming Investment`, holding `80,064,000` shares or `18.91%` of the company and acting in concert with Chairman Ding Lieming and Zhejiang Beicheng Investment for a combined `21.50%` stake), pledged another `4,485,800` shares to Tibet Trust Co., Ltd. (`Tibet Trust`) for one year (`2026-11-19` to `2027-11-19`) for “own operating needs.” That brings Kaiming Investment’s pledged position to **`56,034,800` shares (`69.99%` of its direct holdings and `61.57%` of the controlling concert-party bloc)**, with `48,520,800` pledged shares (`53.31%` of the bloc’s stake) backing **RMB 938.00 million (approx. $129.7 million)** in financing balances scheduled to mature between May and November 2027.

Three verifiable triggers will determine whether `Gevalka`’s European approval translates into meaningful cash flow for Betta: whether the `EMA` Union Register records a Marketing Authorisation transfer from `SFL Pharmaceuticals Deutschland GmbH` to an European commercial partner (or regional out-licensing deal) following publication of the full `Gevalka` Summary of Product Characteristics (`SmPC`); whether Betta submits its Stage IB–IIIB adjuvant `ensartinib` data to the U.S. FDA or `EMA` to match its September 2026 Chinese label; and how both Betta (`RMB 1.19 billion` in current maturing long-term debt) and controlling shareholder Kaiming Investment (`RMB 938 million` in share-pledge loans maturing in 6–12 months) refinance their 2027 maturities.